je.st
news
Tag: merck
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA (pembrolizumab) for Advanced Gastric Cancer
2015-10-22 13:30:46| Merck.com - Product News
Dateline City: ROCKVILLE, Md. and KENILWORTH, N.J. Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer ROCKVILLE, Md.and KENILWORTH, N.J. Language: English read more
Tags: advanced
study
combination
cancer
Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
2015-10-20 16:35:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. New Data Will Also be Presented from Phase 2a C-CREST Trials of Mercks Investigational Triple-Combination Chronic Hepatitis C Therapies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical trials of its investigational treatment portfolio for chronic hepatitis C virus (HCV) are scheduled to be presented at The Liver Meeting 2015 (the 66th annual scientific congress of the American Association for the Study of Liver Diseases) in San Francisco, from Nov. 13-17, 2015. Mercks late-stage investigational portfolio includes elbasvir/grazoprevir1, MK-36822 and MK-84083. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
including
data
present
Merck Animal Health to Sponsor 2015 FFA National Convention & Expo
2015-10-20 02:00:00| ThePigSite - Industry News
US - Merck Animal Health today announced its sponsorship of the 2015 National Future Farmers of America (FFA) Convention & Expo, which will be held Oct. 28-31 at the Kentucky Exposition Center in Louisville, Ky
Tags: health
national
animal
sponsor
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda (pembrolizumab) as First-line Treatment for Advanced Melanoma
2015-10-13 13:30:03| Merck.com - Product News
Dateline City: WILMINGTON, Del. and KENILWORTH, N.J. Pivotal study to evaluate Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with advanced or metastatic melanoma WILMINGTON, Del. and KENILWORTH, N.J. -- Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incytes investigational selective IDO1 inhibitor, with Keytruda (pembrolizumab), Mercks anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. Language: English read more
Tags: for
advanced
include
study
Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment
2015-10-05 23:15:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Co-recipient Dr. William C. Campbell Conducted his Nobel Prize-winning Work at Merck Research Laboratories KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell, a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Mercks development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orClaire Gillespie, 267-305-0932orInvestors:Terri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
treatment
leading
river
Sites : [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] next »